Geode Capital Management
RNAC icon

Geode Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Geode Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.62M Buy
263,694
+8,155
+3% +$58.1K ﹤0.01% 3205
2025
Q4 		$1.84M Buy
255,539
+13,710
+6% +$111K ﹤0.01% 3199
2025
Q3 		$2.47M Buy
241,829
+22,902
+10% +$257K ﹤0.01% 3107
2025
Q2 		$2.28M Sell
218,927
-6,573
-3% -$70K ﹤0.01% 3101
2025
Q1 		$2.97M Buy
225,500
+4,243
+2% +$75.8K ﹤0.01% 2890
2024
Q4 		$3.96M Buy
221,257
+85,557
+63% +$1.73M ﹤0.01% 2854
2024
Q3 		$2.19M Buy
135,700
+2,737
+2% +$42.8K ﹤0.01% 3091
2024
Q2 		$3.59M Buy
132,963
+49,665
+60% +$1.19M ﹤0.01% 2900
2024
Q1 		$1.65M Buy
83,298
+2,026
+2% +$43K ﹤0.01% 3189
2023
Q4 		$1.68M Buy
81,272
+1,780
+2% +$53.1K ﹤0.01% 3168
2023
Q3 		$2.53M Buy
79,492
+583
+0.7% +$19.5K ﹤0.01% 2988
2023
Q2 		$2.65M Buy
78,909
+38,448
+95% +$1.38M ﹤0.01% 3024
2023
Q1 		$1.69M Buy
40,461
+1,302
+3% +$61.2K ﹤0.01% 3108
2022
Q4 		$1.33M Sell
39,159
-1,255
-3% -$53.4K ﹤0.01% 3228
2022
Q3 		$1.99M Buy
40,414
+2,408
+6% +$132K ﹤0.01% 3083
2022
Q2 		$1.49M Sell
38,006
-19,846
-34% -$588K ﹤0.01% 3226
2022
Q1 		$2.13M Sell
57,852
-544
-0.9% -$34K ﹤0.01% 3227
2021
Q4 		$5.71M Buy
58,396
+687
+1% +$73.9K ﹤0.01% 2826
2021
Q3 		$7.2M Buy
57,709
+3,634
+7% +$439K ﹤0.01% 2700
2021
Q2 		$6.78M Buy
54,075
+7,450
+16% +$887K ﹤0.01% 2727
2021
Q1 		$6.33M Buy
46,625
+6,852
+17% +$851K ﹤0.01% 2666
2020
Q4 		$3.61M Buy
39,773
+2,987
+8% +$259K ﹤0.01% 2771
2020
Q3 		$2.74M Buy
36,786
+12,816
+53% +$982K ﹤0.01% 2711
2020
Q2 		$2.04M Buy
23,970
+14,447
+152% +$1.31M ﹤0.01% 2824
2020
Q1 		$688K Buy
9,523
+160
+2% +$15.4K ﹤0.01% 3159
2019
Q4 		$668K Sell
9,363
-24
-0.3% -$1.16K ﹤0.01% 3415
2019
Q3 		$492K Sell
9,387
-97
-1% -$5.16K ﹤0.01% 3474
2019
Q2 		$509K Sell
9,484
-4,278
-31% -$292K ﹤0.01% 3461
2019
Q1 		$978K Buy
13,762
+7,918
+135% +$502K ﹤0.01% 3173
2018
Q4 		$466K Buy
5,844
+886
+18% +$202K ﹤0.01% 3397
2018
Q3 		$2.31M Buy
4,958
+903
+22% +$363K ﹤0.01% 2807
2018
Q2 		$1.61M Buy
4,055
+885
+28% +$314K ﹤0.01% 2981
2018
Q1 		$968K Buy
3,170
+77
+2% +$21.9K ﹤0.01% 3137
2017
Q4 		$910K Buy
3,093
+332
+12% +$145K ﹤0.01% 3138
2017
Q3 		$1.51M Buy
2,761
+731
+36% +$389K ﹤0.01% 2908
2017
Q2 		$1.21M Buy
2,030
+381
+23% +$168K ﹤0.01% 3019
2017
Q1 		$708K Buy
1,649
+93
+6% +$39.1K ﹤0.01% 3171
2016
Q4 		$800K Buy
1,556
+1,184
+318% +$692K ﹤0.01% 3096
2016
Q3 		$159K Buy
+372
New +$145K ﹤0.01% 3671

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Geode Capital Management's RNAC Position: Q1 2026 in Review

Geode Capital Management increased its Cartesian Therapeutics (RNAC) stake by 3.2% in Q1 2026, buying an estimated $58.1K and bringing the position to 263,694 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #3205.

Geode Capital Management first reported a position in RNAC in Q3 2016 and has held it in 39 quarters since. The position peaked at $7.2M in Q3 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Geode Capital Management held 263,694 shares of Cartesian Therapeutics worth $1.62M as of Q1 2026.
  • Geode Capital Management bought 8,155 Cartesian Therapeutics shares in Q1 2026, an estimated $58.1K.
  • Cartesian Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3205 holding.
  • Geode Capital Management first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 39 quarters since.
  • Geode Capital Management's Cartesian Therapeutics position peaked at $7.2M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.